Search GLEAM-DB / CoGenEx-PM3
Advanced search and filters
Input query
Recognized gene
AARS1, AARS2, ABAT, ABCA3, ABCA4 and 18 more
Normalized c.HGVS
c.1043T>G, c.1054G>A, c.1063G>A, c.1082C>G, c.1121G>C and 45 more
Normalized p.HGVS
p.(=), p.(Ala170Ser), p.(Ala170Thr), p.(Ala331Thr), p.(Ala383Thr) and 44 more
Matching records
2545
PM3-positive records
4
Results are ordered by PM3-relevant evidence first. Reviewed source only indicates whether main text, supplementary material, or both were reviewed; it is not the evidence conclusion.
| Gene | Variant | Evidence | PM3 context | Publication | Reviewed source | Actions |
|---|---|---|---|---|---|---|
| ADA |
NM_000022.4:c.778G>A
|
Phase-unconfirmed biallelic evidence
High confidence
|
Possible compound heterozygous with c.646G>A; p.G216R
context: Compound heterozygous candidate
|
38355973
Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency.
Nature medicine, 2024
|
Main article | |
| DNAH1 |
NM_015512.5:c.9814C>T
|
Phase-unconfirmed biallelic evidence
Needs review
|
Homozygous for query variant
context: Homozygous evidence
|
29967352
Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells.
Nature medicine, 2018
|
Supplementary material | |
| TUBGCP6 |
NM_020461.4:c.3226C>T
|
Phase-unconfirmed biallelic evidence
Needs review
|
Homozygous for query variant
context: Homozygous evidence
|
29967352
Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells.
Nature medicine, 2018
|
Supplementary material | |
| ASPM |
NM_018136.5:c.9577C>T
|
Phase-unconfirmed biallelic evidence
Needs review
|
Potential PM3 evidence identified; genotype context not structured
context: PM3 evidence context not structured
|
25326804
Age-related mutations associated with clonal hematopoietic expansion and malignancies.
Nature medicine, 2014
|
Supplementary material | |
| NTRK1 |
NM_002529.4:c.1783G>A
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
41639379
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.
Nature medicine, 2026
|
Main article | |
| RELN |
NM_005045.4:c.10340A>G
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
37188781
Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man.
Nature medicine, 2023
|
Main article | |
| ATM |
NM_000051.4:c.1009C>A
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
36928818
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
Nature medicine, 2023
|
Main article and supplement | |
| RECQL4 |
NM_004260.4:c.2005C>T
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
36732629
Landscape of pathogenic mutations in premature ovarian insufficiency.
Nature medicine, 2023
|
Main article and supplement | |
| PKHD1 |
NM_138694.4:c.6779A>G
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
36658419
Genomic autopsy to identify underlying causes of pregnancy loss and perinatal death.
Nature medicine, 2023
|
Main article and supplement | |
| PKHD1 |
NM_138694.4:c.7238G>A
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
36658419
Genomic autopsy to identify underlying causes of pregnancy loss and perinatal death.
Nature medicine, 2023
|
Main article and supplement | |
| ALMS1 |
NM_001378454.1:c.6854G>A
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
36357675
Rare and common genetic determinants of metabolic individuality and their effects on human health.
Nature medicine, 2022
|
Main article | |
| SLC7A7 |
NM_003982.4:c.272C>A
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
36357675
Rare and common genetic determinants of metabolic individuality and their effects on human health.
Nature medicine, 2022
|
Main article | |
| MUTYH |
NM_001128425.2:c.17C>G
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
35970919
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.
Nature medicine, 2022
|
Main article | |
| ATM |
NM_000051.4:c.3152A>C
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
35962206
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Nature medicine, 2022
|
Main article | |
| ATM |
NM_000051.4:c.3152A>G
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
35962206
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Nature medicine, 2022
|
Main article | |
| ATM |
NM_000051.4:c.6313A>G
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
35962206
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Nature medicine, 2022
|
Main article | |
| MAT1A |
NM_000429.3:c.488G>A
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
32778825
The role of exome sequencing in newborn screening for inborn errors of metabolism.
Nature medicine, 2020
|
Main article | |
| ATM |
NM_000051.4:c.4336G>T
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
31768066
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Nature medicine, 2019
|
Main article | |
| ATM |
NM_000051.4:c.4354G>C
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
31768066
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Nature medicine, 2019
|
Main article | |
| ATM |
NM_000051.4:c.4354G>T
|
No PM3 Evidence Identified
Not assessed
|
No PM3 candidate genotype identified |
31768066
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Nature medicine, 2019
|
Main article | |